Rocket Pharmaceuticals (RCKT) Current Leases (2019 - 2026)

Rocket Pharmaceuticals has reported Current Leases for 8 years, with the latest figure at $1.9 million in Q1 2026.

• Quarterly Current Leases rose 91.45% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 91.45% YoY) and the FY2025 annual result came in at $1.0 million, changed 0.2% from the prior year.
• Current Leases improved to $1.9 million in Q1 2026 per RCKT's latest filing, from $1.0 million in the prior quarter.
• Over five years, Current Leases peaked at $1.9 million in Q1 2026 and troughed at $634000.0 in Q3 2022.
• A 5-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2024: Current Leases soared 179.65% in 2023, then slumped 44.11% in 2024.
• Over 5 years, Current Leases stood at $1.7 million in 2022, then advanced by 3.17% to $1.8 million in 2023, then plunged by 44.11% to $1.0 million in 2024, then grew by 0.2% to $1.0 million in 2025, then surged by 92.02% to $1.9 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.9 million, $1.0 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.